NCT00936208已完成不适用
To Evaluate the Safety, Efficacy, and Protection of Micardis 80 mg/Micardis Plus 80/12.5 mg From Cardiovascular Risks in a 24 Weeks Observational Study in Patients With Essential Hypertension Who Have at Least One Other Known Cardio-vascular Risk Factor
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 3,184
- 试验地点
- 120
- 主要终点
- Change in Diastolic Blood Pressure From Baseline at Week 24
研究概览
简要总结
PRO-POWER is an observational cohort study for a period of 24 weeks. All recruited patients will have essential hypertension. In addition, the patients will have at least one other contributing risk factor for cardiovascular events. The study aims to evaluate the safety, efficacy and protection of Micardis 80mg/Micardis plus 80/12.5mg from cardiovascular risks in patients with essential hypertension
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Change in Diastolic Blood Pressure From Baseline at Week 24
时间窗: Baseline and Week 24
The change from baseline reflects the week 24 value minus the baseline value.
Change in Systolic Blood Pressure From Baseline at Week 24
时间窗: Baseline and Week 24
The change from baseline reflects the week 24 value minus the baseline value.
次要结局
- Change From Baseline in Urinary Microalbuminuria (Urine Dipstick Test Results)(Baseline and Week 24)
- Framingham Score at Week 24(Week 24)
- Change in the Framingham Score From Baseline at Week 24(Baseline and Week 24)
- International Renal Interest Society (IRIS) II Score at Week 24(Week 24)
- Change in the IRIS II Score From Baseline at Week 24(Baseline and Week 24)
研究者
研究点 (120)
Loading locations...
相似试验
已完成
3 期
Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral AntipsychoticsSchizophreniaNCT01081769Janssen-Cilag International NV769
终止
不适用
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)Basal Cell CarcinomaNCT01604252Genentech, Inc.503
已完成
不适用
A Study of Patients With HER2-Positive Metastatic Breast CancerBreast CancerNCT00105456Genentech, Inc.1,000
已完成
不适用
The Prevention Options for Women Evaluation Research (POWER) CohortHIV/AIDSNCT03490058University of Washington2,255
进行中（未招募）
不适用
Eversense® Non-adjunctive Use Post Approval StudyDiabetesNCT04836546Senseonics, Inc.925